Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 14, 2003. The report serves as a notification of changes in directors' interests in the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is limited to corporate governance disclosures regarding share ownership.
Material Changes
On January 13, 2003, the Administrators of the SmithKline Beecham Employee Benefit Trust notified the company that 6,308 Ordinary shares were transferred from the Trust to participants of the SmithKline Beecham 1991 Share Option Plan.
Management Commentary and Risks
The filing notes that the Trust is a discretionary fund where all employees or former employees of GlaxoSmithKline plc and its subsidiaries are potential beneficiaries. Consequently, directors Dr. J.P. Garnier and John Coombe hold an interest in the shares held in the fund in the same manner as other employees. No specific risks, contingencies, or unusual financial items were disclosed in this text.
Investor Verification Points
- Verify the total number of shares held by the SmithKline Beecham Employee Benefit Trust following the transfer of 6,308 shares.
- Confirm the specific shareholding status of directors Dr. J.P. Garnier and John Coombe relative to the Trust.
- Review the terms of the SmithKline Beecham 1991 Share Option Plan to understand the vesting conditions for the transferred shares.